Best Available Therapy (BAT)

DRUG12 trials

Sponsors

Novartis Pharmaceuticals, Incyte Corporation, Sierra Oncology LLC - a GSK company, AOP Orphan Pharmaceuticals AG, Kartos Therapeutics, Inc.

Conditions

Blood Stream InfectionChronic Graft-versus-host-diseaseCorticosteroid Refractory Acute Graft vs Host DiseaseHospital Acquired Bacterial Pneumonia (HABP)Meningitis, BacterialMyelofibrosisMyelofibrosis (MF)Polycythemia Vera

Phase 2

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Kartos Therapeutics, Inc.Post-Essential Thrombocythemia MF (Post-ET-MF), Post-Polycythemia Vera MF (Post-PV-MF), Primary Myelofibrosis (PMF)

Start: 2019-01-15End: 2025-12-31Target: 385Updated: 2023-04-28

Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Not yet recruitingNCT07431307

BioVersys AGBlood Stream Infection, Hospital Acquired Bacterial Pneumonia (HABP), Meningitis, Bacterial +2

Start: 2026-07-01End: 2028-07-01Target: 120Updated: 2026-02-24

Phase 3

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

CompletedNCT00934544

Novartis PharmaceuticalsMyelofibrosis

Start: 2009-07-01End: 2015-03-04Updated: 2019-08-19

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

CompletedNCT01243944

Incyte CorporationPolycythemia Vera

Start: 2010-10-27End: 2018-02-09Updated: 2019-03-06

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

CompletedNCT02101268

Sierra Oncology LLC - a GSK companyPost-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-polycythemia Vera (Post-PV), Primary Myelofibrosis (PMF)

Start: 2014-06-19End: 2019-04-25Updated: 2023-05-23

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

CompletedNCT02218047

AOP Orphan Pharmaceuticals AGPolycythemia Vera

Start: 2014-11-30End: 2021-04-29Updated: 2021-06-01

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

CompletedNCT02913261

Novartis PharmaceuticalsCorticosteroid Refractory Acute Graft vs Host Disease

Start: 2017-03-10End: 2021-04-23Updated: 2023-02-08

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

CompletedNCT03952039

CelgeneMyelofibrosis, Post-Polycythemia Vera, Primary Myelofibrosis

Start: 2019-09-09End: 2025-07-28Updated: 2025-08-28

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

RecruitingNCT04047628

National Institute of Allergy and Infectious Diseases (NIAID)Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

Start: 2019-12-19End: 2029-10-31Target: 156Updated: 2026-01-06

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Active, not recruitingNCT04468984

AbbVieMyelofibrosis (MF)

Start: 2020-08-31End: 2026-12-31Target: 330Updated: 2026-01-09

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Active, not recruitingNCT04576156

Geron CorporationMyelofibrosis

Start: 2021-04-12End: 2028-06-30Updated: 2025-12-04

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

Active, not recruitingNCT06821542

Incyte CorporationChronic Graft-versus-host-disease

Start: 2025-06-04End: 2032-11-30Updated: 2026-03-23

Related Papers

Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3

Blood Advances2025-06-05

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY‐1, SIMPLIFY‐2, and MOMENTUM Trials

eJHaem2025-06-01

IMpactMF, randomized, open-label, phase 3 trial of imetelstat (IME) versus best available therapy (BAT) in patients (pts) with intermediate-2 (INT-2) or high-risk (HR) myelofibrosis (MF) relapsed or refractory (R/R) to Janus kinase inhibitors (JAKi).

Journal of Clinical Oncology2025-05-28

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed<i>/</i>Refractory Myelofibrosis

Blood2024-11-058 citations

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

Blood2024-11-055 citations

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

Blood2024-11-055 citations

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial

Blood2024-11-051 citations

Biomarkers of Renal Health in Patients (pts) Treated with Fedratinib in the FREEDOM and FREEDOM2 Trials

Blood2024-11-051 citations

Effect of Fedratinib Versus Best Available Therapy on Patient-Reported Outcomes in Patients with Myelofibrosis Who Were Previously Treated with Ruxolitinib: Results from the Phase 3 FREEDOM2 Trial

Blood2024-11-05

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response.

2024-11-025 citations

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.

2024-10-167 citations

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

2024-09-0919 citations

Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2

Advances in Therapy2024-07-1111 citations

Association between hemoglobin (Hb) improvement and patient-reported outcomes (PROs) in patients (pts) with myelofibrosis (MF) and anemia: Post hoc pooled analysis of momelotinib (MMB) phase 3 trials.

Journal of Clinical Oncology2024-06-012 citations

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study

Blood2023-11-028 citations

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Blood2023-11-023 citations

Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study

Blood2023-11-021 citations

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Blood2023-11-021 citations

Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)

Blood2023-11-02

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Blood2023-11-02

53 more papers not shown